

(BMSIC/DRUGS/15-05)

Eligibility Criteria as per NIT

Name of Bidder-M/S Scott Edil Pharmacia Ltd.
Corporate Address: 54-55 Industrial Area,Phase-II, Chandigarh-160002
Manufacturing Unit Address: 56 E.P.I.P, PHASE-1, Jharmajri, Baddi.
"Chart has been prepared on the basis of number of downloaded Pg. received (i.e.- 1-194) "


Table with 2 columns: Eligibility Criteria as per NIT and Bidder's response details. Rows 1-17 cover various requirements like Memorandum of Association, Power of Attorney, Product List, Licenses, Certificates, and Financials.

The facts in clause No-1 to 10 and 17 of the provided sheet has been compiled with due diligence and care, on the basis of document provided by BMSICL, in compliance of letter No 515(15) Dt-21.08.2015 of Health Department, Govt of Bihar and letter no BMSIC/40010/2-2014/1678 Dt 18.09.2015 of GM (Supply Chain), BMSICL, Patna. In spite, some inadvertent discrepancies could have been crept in. Humble request to all concerned to bring to notice in due time, if any discrepancies is observed, for rectification.

Handwritten signatures and initials at the bottom of the page.

The facts in pages mentioned against the clause No-
1 to 10 and 17 of this chart has been verified.

Yeshwant

A handwritten signature in blue ink, appearing to be 'Sanku' or similar, written in a cursive style.

Scott Edil Pharmacia limited

PRODUCT LIST APPROVAL & MARKET STANDING STATUS

| S No | NIT S No | Product Name | Product Approval(Pg No)/Sl.no | Remarks | Market Standing for more than three years (Pg No)/Sl.no | Remarks |
|------|----------|--|-------------------------------|--|---|--------------------------|
| 1 | 6 | Albendazole oral suspn. IP-200mg/5ml 10ml | 8.12.11(95) | For export under BP & to be mfg for M/S Interphar & valid upto 29.5.15 | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(64)/(1) | |
| 2 | 7 | Albendazole Tablets 400mg | 11.7.11(96)/05 | To be mfg for M/S Interphar & valid upto 29.5.15 | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(64)/(2) | |
| 3 | 9 | Amikacin Injection IP 100mg/2ml- 2ml | 29.5.10(81)/01 | Pack size not mentioned & validity not mentioned | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(64)/(3) | |
| 4 | 10 | Amikacin Injection IP 250mg/2ml- 2ml | 29.5.10(81)/02 | Pack size not mentioned & validity not mentioned | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(64)/(4) | |
| 5 | 11 | Aminophylline Inj. IP, 25mg/ml- 10ml | Approval not submitted | | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(64)/(5) | Pack size not mentioned. |
| 6 | 15 | Amoxycillin and Potassium Clavulanate Oral Susp. (200+28.5)mg-30ml | 14.5.11(97)/(01) | Pack size not mentioned & valid upto 29.5.15 | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(64)/(6) | Pack size not mentioned. |
| 7 | 16 | Amoxycillin Capsule IP, 500mg | Approval not submitted | | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(64)/(7) | |
| 8 | 17 | Amoxycillin Capsule IP, 250mg | 7.4.11(89)/(04) | Quoted for Amoxycillin Dispersible tab & to be mfg for M/S Interphar | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(64)/(8) | |
| 9 | 18 | Amoxycillin Dispersible Tablets IP, 125mg-kid Tab. | 7.4.11(89)/(03) | valid upto 29.5.15 & to be mfg for M/S Interphar | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(64)/(9) | |
| 10 | 19 | Amoxycillin Oral Suspension IP, 125mg/5ml-60ml | Approval not submitted | | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(64)/(10) | |
| 11 | 20 | Ampicillin & Cloxacillin Inj. (500+500)mg-vial | Approval not submitted | | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(64)/(11) | |
| 12 | 21 | Ampicillin & Cloxacillin Inj. (250+250)mg-vial | Approval not submitted | | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(64)/(12) | |
| 13 | 22 | Ampicillin Inj. IP, 500mg- Vial | Approval not submitted | | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(64)/(13) | |
| 14 | 25 | Atenolol Tab. IP, 25mg | Approval not submitted | | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(63)/(14) | |
| 15 | 26 | Atenolol Tab. IP, 50mg | 6.2.11(94)/(08) | valid upto 29.5.15 | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(63)/(15) | |
| 16 | 29 | Azithromycin Oral Suspension IP, 200mg/5ml- 15ml | 11.10.10(102)/(18) | pack size not mentioned & valid upto 29.5.15 | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(63)/(16) | Pack size not mentioned. |
| 17 | 30 | Betamethasone Cream IP, 0.05%w/w- 15gm | Approval not submitted | | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(63)/(17) | Pack size not mentioned. |
| 18 | 41 | Cefadroxil Tab. 500mg | Approval not submitted | | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(63)/(18) | |
| 19 | 42 | Cefixime Tab. IP 50mg | (98)/(01) | Speciation & dosage form is not as per NIT Specification | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(63)/(19) | |
| 20 | 43 | Cefixime Oral suspension IP, 100mg/5ml- 30ml bott. | Approval not submitted | | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(63)/(20) | |
| 21 | 44 | Cefixime tab. IP, 100mg | 20.4.11(103)/05 | Hand written specification change from USP to IP & to be mfg for M/S Interphar | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(63)/(21) | |
| 22 | 45 | Cefixime Tab. 400mg | Approval not submitted | | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(63)/(22) | |
| 23 | 46 | Cefotaxime Sodium Inj. IP, 1gm- Vial | 13.7.10(83)/13 | valid upto 29.5.15 | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(63)/(23) | |
| 24 | 47 | Cefotaxime Sodium Inj. IP, 250mg- Vial | 4.9.11(84)/05 | valid upto 29.5.15 | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(63)/(24) | |
| 25 | 48 | Cefotaxime Sodium Inj. IP, 500mg- Vial | Approval not submitted | Submitted for ceftriaxone sodium IP inj 500mg(88)/(01) Dt 7.4.11 | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(63)/(25) | |
| 26 | 49 | Cefotaxime Sodium Inj. IP, 125mg-vial | Approval not submitted | | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(63)/(26) | |
| 27 | 50 | Ceftazidime Inj. IP, 500mg-Vial | Approval not submitted | | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(63)/(27) | |
| 28 | 51 | Ceftazidime Inj. IP, 250mg-Vial | Approval not submitted | | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(63)/(28) | |
| 29 | 52 | Ceftazidime Inj. IP, 1g-Vial | Approval not submitted | | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(63)/(29) | |
| 30 | 53 | Ceftriaxone & Salbactam For Inj. 500mg+250mg- Vial | 24.1.11(107)/(03) | valid upto 29.5.15 | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(63)/(30) | |
| 31 | 54 | Ceftriaxone & Salbactam For Inj. 250mg+125mg- Vial | 24.1.11(107)/(03) | valid upto 29.5.15 & to be mfg for M/S Veekay pharma | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(62)/(31) | |
| 32 | 55 | Ceftriaxone Inj. IP, 250mg-Vial | 16.8.10(85)/21 | valid upto 29.5.15 & to be mfg for M/S Interphar | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(62)/(32) | |
| 33 | 56 | Ceftriaxone Inj. IP, 500mg-Vial | 16.8.10(85)/20 | valid upto 29.5.15 | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(62)/(33) | |
| 34 | 57 | Cefuroxime Axetil Tab. IP, 125mg | 11.7.12(82)/02 | valid upto 29.5.15 | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(62)/(34) | |
| 35 | 58 | Cetirizine Hydrochloride Tab. IP, 10mg | valid upto 29.5.15 | valid upto 29.5.15 | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(62)/(35) | |
| 36 | 59 | Cetirizine Syrup IP, 5mg/5ml-30ml | 30.3.12(90)/(07) | valid upto 29.5.15 & Pack size not mentioned. | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(62)/(36) | Pack size not mentioned. |
| 37 | 64 | Ciprofloxacin Eye Drops IP, 0.3% w/v- 5ml Pack | Approval not submitted | | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(62)/(37) | Pack size not mentioned. |
| 38 | 65 | Ciprofloxacin Hydrochloride Tab. IP, 250mg | 18.6.10(86)/(01) | valid upto 29.5.15 | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(62)/(38) | |
| 39 | 67 | Clindamycin Inj. IP, 150mg/ml-2ml Amp/Vial | Approval not submitted | | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(62)/(39) | Pack size not mentioned. |

[Handwritten signature]
[Handwritten signature]

| | | | | | | |
|----|-----|---|-------------------------------------|---|---|--------------------------|
| 40 | 75 | Dexamethosone Inj. IP, 4mg/ml-2ml Vial | Approval not submitted | | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(62)/(40) | Pack size not mentioned. |
| 41 | 76 | Dexamethosone Inj. IP, 4mg/ml-10ml Vial | Approval not submitted | | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(62)/(41) | Pack size not mentioned. |
| 42 | 87 | Doxycycline Cap. IP, 100mg | 2.2.12(93)/01 | valid upto 29.5.15 | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(62)/(42) | |
| 43 | 88 | Drotaverine Hydrochloride Inj. 40mg/2ml-2ml Amp. | Approval not submitted | | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(62)/(43) | Pack size not mentioned. |
| 44 | 89 | Etophylline & Theophylline Inj. (169.4+50.6)mg/ 2ml- 2ml Amp. | Approval not submitted | | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(62)/(44) | Pack size not mentioned. |
| 45 | 97 | Gentamicin Eye Drops IP, 0.3% w/v-5ml | Approval not submitted | | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(61)/(45) | Pack size not mentioned. |
| 46 | 98 | Gentamicin Inj. IP, 40mg/ml-2ml Vial | 29.5.10(81)/(04) | validity & pack size not mentioned | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(61)/(46) | Pack size not mentioned. |
| 47 | 105 | Hydrocortisone Sodium Succinate Inj. IP, 100mg vial | Approval not submitted | | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(61)/(47) | |
| 48 | 128 | Meropenem Inj. IP, 500mg-Vial | 30.4.11(104)/2 | valid upto 29.5.15 & to be mfg for M/S Veritaz Health care ltd | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(61)/(48) | |
| 49 | 129 | Meropenem Inj. IP, 1000mg-Vial | i)30.4.11(104)/3 ii)7.4.11(88)/9 | valid upto 29.5.15 i)To be mfg for M/S Veritaz Health care ltd ii)Approval under USP Specification. | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(61)/(49) | |
| 50 | 130 | Metoclopramide Inj. IP, 5mg/ml-2ml Amp. | Approval not submitted | | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(61)/(50) | Pack size not mentioned. |
| 51 | 131 | Methylergometrine Inj. IP, 0.2mg/ml-1ml Amp. | 27.10.10(87)/05 | valid upto 29.5.15 & to be mfg for M/S Interphar | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(61)/(51) | |
| 52 | 136 | Miconazole Cream IP, 2% w/w- 15gm Tube | Approval not submitted | | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(61)/(52) | Pack size not mentioned. |
| 53 | 139 | Midazolam Inj. IP, 1mg/ml-5ml vial | Approval not submitted | | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(61)/(53) | Pack size not mentioned. |
| 54 | 148 | Ofloxacin & Ornidazole suspen. (50+125)mg/5ml-30ml bottle | (99)/03 | Approval date illegible, valid upto 29.5.15 & pack size not mentioned | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(61)/(54) | Pack size not mentioned. |
| 55 | 151 | Ofloxacin Oral Suspen. IP, 50mg/5ml-30ml bottle | Approval not submitted | | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(61)/(55) | Pack size not mentioned. |
| 56 | 152 | Ondansetron Hydrochloride Inj. 2mg/ml- 2ml Amp. | Approval not submitted | | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(60)/(56) | Pack size not mentioned. |
| 57 | 153 | Ondansetron Oral Solution IP, 2mg/5ml-30ml | 23.1.11(100)/01 | valid upto 29.5.15 & to be mfg for M/S Interphar | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(60)/(57) | Pack size not mentioned. |
| 58 | 154 | Ondansetron Tab. IP, 4 mg | (89)/05 | Approval date illegible,valid upto 29.5.15 & to be mfg for M/S Interphar | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(60)/(58) | |
| 59 | 155 | Ondansetron Tab. IP, 8 mg | Approval not submitted | | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(60)/(59) | |
| 60 | 156 | Oxytocin Inj. IP, 5units/ml-1ml Amp. | 6.9.10(105)/31 | valid upto 29.5.15 | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(60)/(60) | |
| 61 | 157 | Pantoprazole for Inj. 40mg Vial | 7.4.11(88)/02 | valid upto 29.5.15 | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(60)/(61) | |
| 62 | 165 | Piperacillin & Tazobactam for inj. (4g+500mg)-4.5gm | 7.4.11(88)/05 | valid upto 29.5.15 | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(60)/(62) | |
| 63 | 166 | Povidone-Iodine Ointment, 5%w/w -15gm Tube | 29.5.10(106)/9 | valid upto 29.5.15 & Pack size not mentioned. | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(60)/(63) | Pack size not mentioned. |
| 64 | 176 | Rabeprazole Sodium for Inj. 20mg-Amp/Vial | Approval not submitted | | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(60)/(64) | |
| 65 | 208 | Xylometazolin Nasal Drops IP, 0.1%w/v-10ml | 13.8.10(91)/08 | valid upto 29.5.15 & Pack size not mentioned. | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(60)/(65) | Pack size not mentioned. |
| 66 | 209 | Xylometazolin Nasal Drops IP, 0.05%w/v-10ml | 4.1.12(79)/06 | valid upto 29.5.15 & Pack size not mentioned. | vide ref no.HFW-II(Drugs)106/05(vol v) HP Baddi dt 24.8.15(60)/(66) | Pack size not mentioned. |

[Handwritten signature]
Vashwani